A new review in Advanced Cancer Research details how post-translational modifications regulate KRAS localization, activity, ...
A preclinical study shows that combining KRASG12D inhibition with CTLA-4 blockade dismantles a TGF-beta-driven regulatory T ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, ...
A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...
FDA grants TRE-515 Fast Track status with KRAS G12C inhibitors for previously treated NSCLC. See what the designation means for development and review.
RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “In preclinical studies, the combination of RAS (ON) multi-selective and ...
The KRAS G12D mutation, long considered "undruggable" for over 40 years, has emerged as a high-stakes battleground for global pharmaceutical ...
Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...
G12C therapies broaden patient reach, while biomarker-led combinations and US-focused launches can unlock unmet demand and strengthen competitive positioning.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
Most of the KRAS inhibitors that have produced clinical data in biliary tract cancer so far target KRAS G12C, a mutation found in only a minority of patients with KRAS-mutant dise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results